Author:
Latysheva T V,Latysheva E A,Shubina O V
Abstract
Goals. To reveal the clinical efficacy and safety of Asmanex in patients with moderate and severe bronchial asthma (BA), treated with inhaled and/or systemic glucocorticosteroids (GCS), depending on the severity and level of control. Methods. 40 patients (age 18 to 65 years) were treated with Asmanex with equivalent to prior therapy with inhaled corticosteroids (ICS) doses or in combination with systemic corticosteroids prior therapy (without increasing the dose of systemic corticosteroids) for 3 months. Efficacy was assessed before and after the treatment on a background of Asmanex treatment by the need of additional using of agonists of β 2-adrenoreceptors, severity of daytime and nighttime asthma symptoms, dynamics of spirometry parameters. The efficacy of Asmanex was compared with the original baseline therapy of other inhaled corticosteroids at equivalent doses using the new delivery system.
Reference35 articles.
1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998, v. 351, p. 1225-1232.
2. Adams P.F., Marano M.A. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 1995, No. 10, р. 193.
3. Eagan T.M., Brogger J.C., Eide G.E., Bakke P.S. The incidence of adult asthma: a review. Int. J. Tuberc Lung Dis. 2005, v. 9 (6), р. 603-612.
4. Grundy J., Matthews S., Bateman B. et al. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J. Allergy Clin. Immunol. 2002, v. 110, p. 784-789.
5. Variations in the prevalence of respiratory symptoms, self reported asthma attacks and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. 1996, v. 9, p. 687-695.